InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Europe Download

  • A pivotal year for the EU trade mark system

    With a new Trade Mark Directive and Regulation, and the publication of its next five-year plan, 2016 is proving to be a key year for the EUIPO (formerly OHIM). James Nurton reports

  • A guide to European IP post-Brexit

    Morten Garberg and Dirk Schüssler-Langeheine of Hoffmann Eitle outline how Europe’s IP regime may look after Brexit and explain what IP owners should be doing to prepare for it

  • A view from the outside

    As the UK seeks to forge a new relationship with the EU, Andreas Sætre Hanssen of Onsagers explains how another non-member, Norway, has managed its IP regime

  • Securing software patents through the EPO

    Some IP owners doubt that software can be protected in Europe. David Robinson and Mike Williams of Marks & Clerk explain why they are wrong, and what owners of computer-implemented inventions can do to maximize their chances of securing a patent

  • The cost factors that will shape your European patent strategy

    Multinational companies and SMEs will need to think carefully about whether using the Unitary Patent and the UPC will save them money. Micaela Modiano and Alessandro Sanchini of Modiano outline the factors they need to take into account

  • Changing places: Why Milan should host a UPC central division court

    The UK referendum result means that London is unlikely to play host to a UPC central division court. Cristina Biggi of Bugnion makes the case for Milan taking on the role

  • Unconventional trade marks in the 21st Century

    Trade mark proprietors continue to push the boundaries of protection for non-traditional trade marks. Simon Barker of Freeths explains how their marks can be protected in Europe and the UK

  • Fighting unfair competition in the UK and Germany: An Anglo-German perspective

    Germany and the UK both offer brand owners the means to protect unregistered IP rights. Angela Fox and Michael Nielen of Maucher Jenkins outline the similarities and differences between the rules in the two countries

  • What Brexit means for the European patent system

    The UK referendum result has created confusion over the future of the Unitary Patent and the Unified Patent Court. Marianne Schaffner of Dechert argues that EU member states must push ahead with the plan

  • Do patents get in the way of feeding the world?

    Technological changes to the way that plants are developed and grown pose challenges to the way that plant breeders’ rights are protected. Ylva Skoglösa and Isabel Cantallops Fiol of Valea outline the problems and offer potential solutions

  • How to enter the Russian pharmaceutical market

    The emergence of big domestic drug companies is reshaping Russia’s pharmaceutical patent landscape. Mikhail Khmara and Yana Lipatova of ARS-Patent explain how originator and generic companies can navigate the country’s changing IP rules


profile

Managing IP

ManagingIP

ManagingIP profile

RT @mdloney: SCOTUS TC Heartland v Kraft Foods Group Brands oral argument transcript is up! https://t.co/v29vEKCILp

Mar 27 2017 07:50 ·  reply ·  retweet ·  favourite
ManagingIP profile

Likely to be an important question for some applicants, with UPC due to come into force in December this year https://t.co/ASuSYUpRqd

Mar 27 2017 04:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

Don't forget to sign up for our next webinar, on IP in Asia, this Thursday at 3pm (London) https://t.co/gh3Ka8t9q1 @inoviaIP @Minesoftnews

Mar 27 2017 04:38 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements